Korea Institute of Science and Technology

D. R. Nano Co., Ltd.

K2b Therapeutics, Inc.

Seoul National University

Kist (Korea Institute of Science and Technology)

Ick Chan Kwon

Sehoon Kim

Sun Hwa Kim

Kwangmeyung Kim

Kwang Meyung Kim

Kuiwon Choi

Hong Yeol Yoon

Inchan Youn

Jay S Kim

Yoo Soo Yang

Jong Won Lee

Ju Hee Ryu

In-San Kim

Seo Young Jeong

In Chan Youn

HoWon J Kim

Eunjung Lee

So Jin Lee

Hesson Chung

Young-Ji Ko

Hyung Jun Ahn

Hyun Su Min

Jong Hwan Kim

Sang-min Lee

Seung Yong Lee

Jeongyun Heo

Jong-Ho Kim

Sangyoup Lee

Kui Won Choi

Chang-Keun Lim

Myung Sook Huh

Yoosoo Yang

Juho Park

Heebeom Koo

Sojin Lee

Jai Kyeong Kim

Jin Seok Kim

Ji Yoon Kang

In San Kim

Yong-Hee Kim

Sang Yoon Kim

Eun Gyeong Yang

Hak Suk Chung

Man Kyu Shim

Hyosuk Kim

Jae Hyung Park

Jun Uk Chu

Yong Woo Cho

Jinsu An

Mihue Jang

Nam-Hyuk Cho

Eun-Jeong Yang

Jin Su An

Jun Kyo Suh

Eun Sung Jun

Chong Rae Park

Seung Young Lee

Hye-Sun Kim

Sang Bong Seo

Yoen Ju Son

MyungSook Huh

Kwangmyeng Kim

Ji Young Yhee

Yu Hyun Ji

Gi-Jung Kwak

Yuhyun Ji

Myungn Sook Huh

Sang-Min Lee

Sang Bong Jakwang Co Ltd Seo

Kwangmyung Kim

Seunglee Kwon

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a cancer cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the cancer cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.

The present invention relates to a method for inducing trans-differentiation of cardiomyocytes based on exosome, and more particularly, to a method for inducing trans-differentiation of a fibroblast into a cardiomyocyte, comprising the steps of: isolating exosomes in a culture medium during a process of differentiating a stem cell into the cardiomyocyte; culturing a fibroblast in a cardiomyocyte reprogramming medium containing the isolated exosomes; and culturing the fibroblast cultured in a cardiomyocyte differentiation medium containing the isolated exosomes.

Method for inducing trans-differentiation of cardiomyocytes based on exosome

A probe for measuring the activity of caspase-1 according to the present disclosure can specifically image cells or tissues where inflammatory response is induced because it is cleaved by reacting specifically with the active caspase-1 enzyme in vivo and in vitro and re-emits fluorescence. The probe for measuring the activity of caspase-1 can be used for various purposes, such as for imaging of cells or tissues where inflammatory response is induced, as a drug carrier, for screening of a drug inhibiting inflammatory response, etc. The probe for measuring the activity of caspase-1 is applicable both in vivo and in vitro, and can be used for various applications such as high-throughput screening for new drug development, early diagnosis of diseases, etc.

Probe for measuring activity of Caspase-1 and composition for diagnosis of inflammatory diseases containing same

The present invention is related to a method for treating cancer by using siRNA nanocomplex consisting of a nucleic acid molecule, a monocationic drug and a biocompatible polymer surfactant. The present nanocomplex can deliver an active ingredient (for example, a nucleic acid molecule and monocationic drug) into a cell/tissue of interest in a stable manner, and may be effectively applied for treating or detecting diverse disorders (practically, cancers).

Method of treating cancer by using siRNA nanocomplexes

A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.

Immunoregulatory protein-siRNA complex having anticancer activity

The present invention relates to a novel anti-miRNA single-stranded nucleic acid maleimide derivative, which comprises an anti-miRNA single-stranded nucleic acid having a nucleic acid sequence complementary to a nucleic acid sequence of an miRNA. Further, the present invention provides an anti-miRNA single-stranded nucleic acid-serum albumin conjugate in which serum albumin is covalently bonded to the anti-miRNA single-stranded nucleic acid maleimide derivative via the maleimide group.

Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite

Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.

Tumor cell-specific responsive self-assembling drug nanoconjugate

A bacterium that constitutively produces monophosphoryl lipid A (MLA) and a method of producing MLA by using the bacterium may simply produce MLA and a derivative thereof without acid hydrolysis, reduce a probability of natural mutation, and increase yields of MLA and a derivative thereof by constitutive expression of the MLA and derivative thereof.

Bacterium constitutively producing monophosphoryl lipid A and method of producing monophosphoryl lipid A by using bacterium

The present invention discloses a method for diagnosing and detecting cancer by bioimaging using methylene blue nanoparticle as a contrasting agent. The methylene blue nanoparticle of the present invention for use as a topical cancer targeting phototherapeutic agent is composed of only a material of which the composition is clinically used or derived from human bodies, and thus a nanopreparation in which a barrier to clinical entry is low and the possibility of commercialization is very high, exhibits near-infrared fluorescence along with cancer targeting property, a capacity of generating a singlet oxygen and the like. Therefore, the methylene blue nanoparticle in the present invention is able to detect cancerous cells by emitting visible light in irradiation conditions.

Method of using methylene blue nanoparticle for detecting cancer by bioimaging

The present invention discloses a method for treating cancer disease by photodynamic therapy. The photodynamic therapy in the present invention uses a methylene blue nanoparticle as a therapeutic agent. The methylene blue nanoparticle of the present invention for use as a topical cancer targeting phototherapeutic agent is composed of only a material of which the composition is clinically used or derived from human bodies, and thus a nanopreparation in which a barrier to clinical entry is low and the possibility of commercialization is very high, exhibits near-infrared fluorescence along with cancer targeting property, capacity of generating a singlet oxygen and the like. Therefore, the methylene blue nanoparticle in the present invention is able to cure cancer cells by cell apoptosis in irradiation conditions.

Method for treating cancer by photodynamic therapy

A RNA/DNA nanoparticle for delivering siRNA where a RNA transcript including at least one hairpin structure hybridizes DNA-cholesterol conjugate and folate-DNA conjugate including a complementary sequence to the RNA transcript, and a composition including the RNA/DNA nanoparticle is provided. More specifically, because various siRNA used for different applications can be contained in the RNA/DNA nanoparticle for delivering siRNA at a high loading efficiency, and has stability to the outer attacks such as nuclease degradation. The RNA/DNA nanoparticle siRNA can be prepared by self-assembly without using polycationic agent which is harmful agent for body. The folate targeting to various cancer cells can accumulate the nanoparticle selectively on target cancer cell after intravenous injection, and make excellent gene-silencing effect inside the cancer tissue, thereby being used as a good agent for treating cancers.

RNA/DNA nanoparticle for siRNA target-specific delivery and vehicle including the same

The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.

Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same

The present invention relates to a nanocomplex, and a pharmaceutical composition, a drug delivery system and a drug delivery method using the same. The present nanocomplex consists of a nucleic acid molecule, a monocationic drug and a biocompatible polymer surfactant, and not only has a hydrodynamic size of 10 nm or less, but uniformly distributes as a colloidal form in an aqueous environment. In addition, the nanoscale colloidal formulation of the present invention could protect the nucleic acid molecule from a nuclease (for example, serum nucleases) rich in a physiological environment through the formulation of a stable monocomplex, and provide improvement of cell penetration and in vivo delivery via a micellar structure as well as further protection of the nucleic acid molecule by a micellar passivation. Therefore, the present nanocomplex and a composition and system using the same can deliver an active ingredient (for example, a nucleic acid molecule and monocationic drug) into a cell/tissue of interest in a stable manner, and may be effectively applied for treating or detecting diverse disorders (practically, cancers).

Nanocomplexes for co-delivering a drug and siRNA and uses thereof

Growing community of inventors

Seoul, South Korea

Ick Chan Kwon